Urea has been reported to be a competitive inhibitor of urinary N-acetyl-f-D-glucosanuinidase (NAG; EC 3.2.1.52) and its isoenzymes (1, 2). The inhibitory effect can be eliminated by pretreatung the urine sample with gel-filtration (3) or by diluting the sample 15-20-fold within the assay mixture (1,2, 4). When working at the pH optimum of the enzyme (pH 4.5), one can further lower the urea inhibition by increasing the substrate concentration (2). In some published rate-assay procedures, the recommended pH of the assay is 5.7-6.25, well away from the optimum pH (5, 6). Although the urea inhibition effect is of primary importance, in that NAG is assayed widely in clinical routine, the pH dependence of the inhibition has not been investigated. In the present study, we investigated how the pH influences the inhibitory effect of urea by using an assay (4) based on VRA-GlcNAc {ammonium 5-[4-(2-acetamido-2-deoxy-(3-D-glucopyranosyloxy)-3-methoxyphenylmethylene}-2-thioxothiazolidin-4-one-3-ethanoate} substrate.
Random (untimed) urine samples from five men and seven women, ages 22 to 49 years, were used in this study.
NAG indices were determined
with the VRA-GlcNAc substrate (PPR Diagnostics, London, UK). Assays (4) were carried out at the pH optimum (pH 4.5) and also over the pH range 5.0-6.5 because higher values are used in some rate assays. The reaction rates were measured before and after the addition of solid urea to samples previously dialyzed to remove any endogenous urea. The final concentration of urea used was 0.6 mol/L-chosen because this can be regarded as the upper limit of normal in human urine (1, 2). The significance of the increase in mean urea inhibition values with increasing p11 was determined by using two-way analysis of variance (ANOVA in Minitab) and analysis of covariance (ANCOVA in Minitab). Kinetic studies were also performed in citric acid-disodium hydrogen phosphate buffers (0.15 mol/L, containing sodium aside, 3 mmol/L) at three different pH values (pH 4.5, 5.0, and 5.5) at 37#{176}C; the rate of reaction at pH 6.0-6.5 was too slow to allow accurate kinetic analysis. We preincubated the reaction mixtures (0.75 mL) for 5 mm before adding the 50-L urine sample to start the reaction. After incubation for 30 miii, the samples were assayed as described previously (4 The standard VRA-GIcNAcassay includes a 15-fold sampledIlution (4);
hence,the urea concentrationin the reaction mixtureswas40 mmol/L b ooVmin per mmolof creatinine. Normal creatinine concentration was
C By two-way ANOVA; NS, notsignificant. n = 12 each.
mixture.
Kinetic parameters
were determined as described previously (7, 8) .
Normal NAG index values decreased to one-third their initial values when the pH was increased by two pH units above the optimum in the assay (Table 1) . Meanwhile, the inhibition in the presence of 0.6 mol/L urea increased fourfold with increasing pH. The increase in the mean urea inhibition was significant at pH 5.5 (P <0.05), pH 6.0 (P <0.01), and pH 6.5 (P <0.01) ( Table 1 ). The analysisof covariance of the urea inhibition was highly significant (P <0.000), confirming that the urea inhibition increases with increasing pH. Assessing the experimental data by Lineweaver-Burk linearization demonstrated that urea inliibits urinary NAG in a mixed-type manner rather than competitively. Therefore, in addition to the competitive inhibition constant (Kr), the uncompetitive inhibition constant (K') was also taken into account (9) when we analyzed the results. The K values were very similar to those previously reported by Mueller et al. (2) and were independent of pH (106 mmol/L at pH 4.5 to 115 mmol/L at pH 5.5). In contrast, the uncompetitive part of the inhibition increased with pH (with K1' decreasing from 1000 mmol/L at pH 4.5 to 340 mmol/L at pH 5.5). Consequently, there is an overall increase in urea inhibition. This finding agrees with and could well explain the increase in the mean urea inhibition values shown in Table 1 .
Bondiou and her coworkers (1) described a competitive type of urea inhibition for urinary NAG A and B isoenzymes, Briefly, the assay follows this format: a coated microtiter plate binds mouse monoclonal antibody against the human IgG subclass (1 or 4) Organization reference standards demonstrated that the kits had acceptable accuracy.
The CV within a microtiter plate was determined to be 5% for the IgG1 kit and 3% for the IgG4 kit. The CV forassays performed on different days was 9.5% for the IgG1 kit and 6% for the IgG4 kit.
Because all of our samples had the same cell-culture media matrix, we at first thought that blank-correction for nonspecific binding due to components (such as rheumatoid classes was <0.3% (Table 1) . Without using blank-corrected wells, the cross-reactivity against human IgG3 was high: -85% for the IgG1 kit and 4% for the IgG4 kit. Further testing against monoclonal immunoglobulins demonstrated that IgG3 molecules having a lambda light chain, but not those having a kappa light chain, bound nonspecifically to the capture antibody of these sandwich ELISAs.
Apparently the capture antibody of the Zymed human IgG subclass kits binds to an epitope shared by IgG3 and IgG1, consisting of portions of the lambda light chain and the gamma heavy chain. IgG3 and IgG1 also appear to share an epitope in the lambda and gamma chains that the Zymed capture antibody binds to a lesser degree. Therefore, to obtain accurate results, it is extremely important to use sample blanks for the Zymed human IgG1 and IgG4 ELISA kits.
